Brief: PharmAust Receives Orphan Drug Designation From US FDA For Monepantel
17/05/2024 02:27
May 17 (Reuters) - PharmAust Ltd PAA.AX :
* RECEIVED ORPHAN DRUG DESIGNATION FROM US FDA FOR
MONEPANTEL &
ITS TREATMENT OF MOTOR NEURONE DISEASE / AMYOTROPHIC LATERAL
SCLEROSIS
Further company coverage: PAA.AX
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon jumps on potential for neurodegenerative drug approval
Brief: Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDA
Brief: Neurizon Therapeutics Says Dr Chris Bremer Commences As CEO
Brief: Neurizon Therapeutics Appoints Chris Bremer As Chief Executive Officer
Brief: Neurizon Therapeutics Enters Strategic Research And Development Financing Facility